Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference
Boehringer Ingelheim Pharmaceuticals has announced that 29 abstracts from the company's respiratory portfolio will be presented at the 2015 American Thoracic Society (ATS) International Conference taking place 15–20 May in Denver, including data on investigational therapies for chronic obstructive pulmonary disease (COPD) and asthma, and on approved products for idiopathic pulmonary fibrosis (IPF) and COPD. Of the 29 accepted abstracts, 19 are on COPD, including key data from the Phase III TONADO trials of late-stage, investigational tiotropium/olodaterol Respimat.
"We are proud of our long-standing commitment to ongoing innovation in discovering and developing new treatments for serious lung conditions where there is an unmet need," said Danny McBryan, vice president, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. "We look forward to sharing our asthma, IPF and late-stage COPD data at ATS, as we continue to advance our portfolio of respiratory products."
In addition to the data presentations, Boehringer Ingelheim will provide attending healthcare professionals with several educational opportunities, including an Industry Theater Presentation, "The Role of Bronchodilators in the Long-Term Maintenance Treatment of Patients with COPD: A Review of the Data" (18 May at 11:45 am MT), and a dinner symposium featuring a panel of experts, "Selection of Long-Term Maintenance Therapy for Patients With COPD" (19 May at 6:30 pm MT).
Chronic Obstructive Pulmonary Disease (COPD) Presentations
Sub-analyses from the TONADO trials investigating the safety and efficacy of tiotropium/olodaterol Respimat in patients with COPD will be presented.
Tiotropium/olodaterol Respimat is an investigational maintenance treatment for patients with COPD and includes tiotropium, the active ingredient in Spiriva Respimat (tiotropium bromide) Inhalation Spray and Spiriva HandiHaler (tiotropium bromide inhalation powder), combined with olodaterol. Tiotropium/olodaterol Respimat is not currently approved and its efficacy and safety is being evaluated. Additional analyses will also be presented from the ANHELTO studies of Spiriva HandiHaler and olodaterol Respimat versus Spiriva HandiHaler alone, as well as the WISDOM trial evaluating the stepwise withdrawal of inhaled corticosteroids (ICS) in COPD. Also being presented are further analyses from the TIOSPIR trial comparing Spiriva Respimat and Spiriva HandiHaler.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance